INTRODUCTION
Interstitial lung diseases (ILDs) are a heterogeneous group of disorders with manifestations including dyspnea, hypoxia, cough, impaired pulmonary function, and various patterns of inflammation and fibrosis evident on radiologic or histopathologic evaluation of the lung. Although some ILDs are associated with an underlying systemic condition, such as rheumatoid arthritis (RA) or dermatomyositis, others are idiopathic and without a recognized driver of disease initiation or progression [1] . Microbes, including viruses [2] , bacteria [3] , and environmental fungi [4] have long been hypothesized to play a role in the pathogenesis of ILDs. Culture-dependent microbiological techniques have, to date, limited most researchers to focus on potential viral triggers in ILDs. However, advances in modern molecular sequencing technology over the past decade have allowed a more systematic study of the role of bacterial communities, or the 'microbiome', in lung health and disease, using culture independent approaches.
Evidence now suggests that increased bacterial burden and/or abundance of potentially pathogenic bacteria may drive disease progression, acute exacerbations, and mortality in idiopathic pulmonary fibrosis (IPF) [5,6 & ,7] . These observations, along with studies suggesting that antibiotic administration or immunization against pathogenic organisms may improve IPF outcomes [8, 9] , have created enthusiasm for evaluation of the lung microbiome as a therapeutic target. Although most research to date has focused on IPF specifically, we are also now beginning to understand the composition of the lung microbiome in other ILDs. In those ILDs associated with immune system activation (i.e., connective tissue disease associated ILD or hypersensitivity pneumonitis), a different role for the lung microbiome may emerge, shaped by interaction of the host immune system with the local environment. This review article summarizes what is known about the lung microbiome in ILDs, and poses considerations of the microbiome as a therapeutic target.
THE HUMAN AIRWAY CONTAINS A COMPLEX AND DYNAMIC MICROBIOTA
Modern methods of high-throughput molecular analysis have allowed for efficient culture-independent study of microbial contents in biologic samples. The gene for the variable 16S region of bacterial ribosomal RNA (rRNA) is selectively amplified and sequenced. Sequences are then grouped based on genetic similarity into operational taxonomic units (OTUs), with individual species identified by referencing a database [10, 11] . The bacterial community composition at various body sites is referred to as the microbiome.
Healthy lungs have historically been described as sterile, but use of modern sequencing methods has revealed a complex and dynamic microbiota in the respiratory tract. Bacterial communities in the lung appear to immigrate from the mouth [12, 13] , most commonly via microaspiration but also by direct dispersal along the mucosa [14 & ]. The quantity and composition of the microbiome is influenced by rate of immigration and emigration via mucociliary clearance or host defense mechanisms, with local growth factors contributing very little to microbiome composition in healthy lungs [15] .
AN ALTERED LUNG MICROBIOME PREDICTS DISEASE PROGRESSION IN IDIOPATHIC PULMONARY FIBROSIS
It is believed that an impaired wound healing response in genetically susceptible individuals results in the progressive architectural distortion of the lung in IPF [16] . The 'wound' initiating the aberrant healing response remains unclear, with environmental exposures (including cigarette smoking and industrial dusts), gastroesophageal reflux (GER), and microbial agents hypothesized to contribute [17] . Lending support to the idea that microbes specifically contribute to disease progression in IPF is the finding that immunosuppressive therapy significantly increases the risk of death and other adverse events [18] .
The contribution of viral infections, including hepatitis C virus, transfusion transmitted virus, and human herpes virus, have been extensively studied, but with conflicting results across studies leading to doubt about their importance in disease pathogenesis [19] . Human herpes viruses (including EpsteinBarr virus, cytomegalovirus, herpes simplex virus, and human herpes virus-7 and human herpes virus-8) have been identified in the lung tissue of a greater proportion of IPF patients as compared with controls [2] , and similar viruses enhance fibrosis in animal models [19] . These data are confounded by the high rate of receipt of immunosuppressive drugs in IPF patients, but could suggest a role of viruses as co-factors driving fibrosis progression.
The incorrectly held doctrine of lung sterility outside of clinical infection meant historically little work has evaluated the role of bacteria in IPF. However, recent research has characterized the lung microbiome in stable IPF, and linked microbial composition and bacterial burden with disease outcomes. Han et al. [5] evaluated the lung microbiome in IPF patients enrolled in the Correlating Outcomes with biochemical Markers to Estimate Timeprogression (COMET)-IPF study. Prevotella, Veillonella, and Cronobacter species (spp.) were the most prevalent and abundant OTUs across this IPF cohort. After adjusting for age, sex, smoking status, GER, baseline pulmonary function and 6-minute-walk desaturation status, having a specific Streptococcus or Staphylococcus OTU present with relative abundance above a specified threshold was associated with a clinically significant reduction in progression-free survival time. Of note, one or both OTUs were identified in less than half of the cohort, making it unlikely that these organisms completely explain disease pathogenesis [5] . The finding that potentially pathogenic organisms (here, Streptococcus and Staphylococcus sp.) are associated with increased risk of disease progression in humans is
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in line with the findings in two separate mouse models, where infection with Streptococcus pneumoniae results in exacerbation of existing lung fibrosis [8] .
Molyneaux et al. [7] prospectively enrolled IPF patients, chronic obstructive pulmonary disease (COPD) patients, and normal controls, comparing microbial composition in bronchoalveolar lavage fluid. IPF patients had significantly higher bacterial burden compared with COPD and healthy controls. Although the most abundant species in both IPF and combined controls were Streptococcus, Prevotella, and Veillonella spp., IPF patients had significantly less diverse bacterial communities, and were more likely to harbor potentially pathogenic Haemophilus, Neisseria, and Streptococcus spp. compared with controls. Among IPF patients, having a higher bacterial load was associated with a significantly reduced progression-free survival time compared with having a relatively lower bacterial load, an effect independent of age and smoking status. Unlike the results of Han et al., no specific organism was associated with increased risk of disease progression. Interestingly, IPF patients harboring a MUC5B minor allele genotype, previously associated with increased risk of developing IPF and playing a role in mucociliary clearance [20, 21] , had significantly lower bacterial burden compared with IPF patients not harboring this genotype [7] . In a separate IPF cohort, Molyneaux et al. [6 & ] found that IPF patients experiencing an acute disease exacerbation had a bacterial burden which was four times higher compared with stable IPF controls matched by age, sex, smoking history, and baseline lung function. Exacerbated patients had relatively higher abundance of Proteobacteria sp., including significantly higher relative abundance of the potential pathogens Campylobacter and Stenotrophomonas spp., compared with controls [6 & ]. Interestingly, Campylobacter is best known as a gastrointestinal pathogen. This finding supports the idea that GER may contribute to exacerbations in IPF [17, 22] . Initial work examining the fungal microbiome in IPF suggests there are no significant differences compared with healthy controls [23 & ]. Figure 1 summarizes evidence for an association of lung microbiome alterations with disease progression in IPF. ] found TLR9 expression to be positively correlated with Staphylococcal OTU1348, which also predicted in-vitro fibroblast TLR9 responsiveness (measured by >2-fold increase in alpha-SMA expression post-stimulation), suggesting that TLR9 signaling may depend on lung microbial communities. A specific Staphylococcal OTU was also associated with accumulation of CXCR3þ CD8þ T cells, which are involved in Th1 pathway signaling. Enrichment of this OTU in the lungs of IPF patients was previously associated with reduced progression-free survival [5] . It was also recently reported that administration of aerosolized inhaled interferon-gamma to IPF patients for therapeutic purposes has little impact on lung microbiome composition, supporting the idea that the lung microbiome has an independent effect on the host immune milieu [27 & ]. Taken together, these data lend further support for a link between lung microbiome alterations, an associated aberrant host response, and disease pathogenesis in IPF. Whether an abnormal microbiome triggers a host response, or an abnormal host response alters the microbiome remains unclear. Hypotheses and evidence for the role of bacteria in IPF pathogenesis are summarized in Figure 2 .
UNDERSTANDING INTERACTIONS BETWEEN HOST AND LUNG MICROBIOME IN IDIOPATHIC PULMONARY FIBROSIS

LUNG MICROBIOME ACROSS INTERSTITIAL LUNG DISEASES
Several studies have evaluated the lung microbiome in ILDs other than IPF. The lung microbiome is proposed as a potential driver of injury and host response in IPF, with influx of organisms from the mouth (possibly originally sourced from the gastrointestinal tract) and altered mucociliary clearance with abnormal anatomy hypothesized to shape alterations to the microbiome. Conversely, limited evidence suggests that the immune system or other disease-specific host factors may have a greater role in shaping the lung microbiome in non-IPF ILD. Granulomatosis with polyangiitis (GPA) patients tend to harbor Staphylococcus aureus in the nasal passages, and culture of BAL fluid identified this pathogen in the lungs of over one-third of GPA patients compared with none of the concurrently studied IPF controls [3] . Furthermore, BAL fluid supernatant from GPA patients acts as a growth factor for cultured S. aureus, whereas fluid from FIGURE 1. Evidence for an association of lung microbiome alterations with disease progression in idiopathic pulmonary fibrosis (IPF). In panel a, Molyneaux et al. [7] demonstrated that IPF patients had significantly higher bacterial burden compared with chronic obstructive pulmonary disease (COPD) and healthy controls. In panel b, the same study by Molyneaux et al. [7] demonstrated that among IPF patients, higher bacterial burden in the lungs is associated with significantly shortened progression-free survival. In panel c, Han et al. [5] demonstrate in a separate IPF cohort that having a specific Streptococcus or Staphylococcus operational taxonomic unit (OTU) present with relative abundance above a specified threshold is associated with a clinically significant reduction in progression-free survival time. Shown here is a Kaplan-Meier plot with patients stratified by threshold of 3.9% relative abundance of Streptococcus OTU 1345. Plots of panels a and b reproduced with permission from [7] . Panel c plot is reproduced with permission from [5] .
IPF patients and normal controls does not promote growth [3] . A recent study evaluated the lung microbiome composition in patients with early RA (60% with abnormalities on chest computed tomography), sarcoidosis, and healthy controls [28 & ]. Similar to observations in IPF patients [7] , diseased patients had reduced bacterial species diversity compared with controls, with selective absence of Paraprevotellaceae, Chryseobacterium, and Burkholdelia spp. in diseased lungs [28 & ]. Furthermore, community structure differed between patients and controls, but was similar in RA compared with sarcoidosis cohorts, despite significant differences in age and smoking history. This observation led the authors to hypothesize a role of airway mucosal inflammation in shaping the lung microbiome structure in autoimmune/inflammatory diseases [28 & ]. However, these results are somewhat contradictory to previous findings that community diversity and structure was not different when comparing mixed ILD, sarcoidosis, and healthy controls [29] .
FROM LUNG MICROBIOME ALTERATIONS TO TREATMENT STRATEGIES IN INTERSTITIAL LUNG DISEASES
The majority of our knowledge to date regarding the impact of the lung microbiome in fibrotic lung disease relates specifically to IPF and can be summarized as follows: increased bacterial burden and overrepresentation of potential pathogens are associated with disease exacerbations and progression [5,6 & ,7] ; there appears to be a specific host immune response to an altered lung microbiome and associated with prognosis [24
and there is clear harm in administration of immunosuppressive drugs to patients with IPF [18] , possibly due to propagation of detrimental microbiome alterations. Therapy directed at the microbes themselves could include antibiotics to reduce bacterial burden or target specifically identified organisms, vaccination to reduce the risk of infection with specific pathogens, or interventions aimed at reducing immigration of bacteria to the lungs (i.e., reducing aspiration from the oropharynx).
Prior to clear knowledge of specific microbiome alterations in ILD, Shulgina et al. [9] conducted a randomized, placebo-controlled trial assessing the impact of co-trimoxazole on 12-month FVC change in patients with idiopathic interstitial pneumonia (>90% of the cohort had IPF). This study was unable to demonstrate that co-trimoxazole reduces disease progression (as measured by change in forced vital capacity in 12-months, the primary endpoint) or death. With a high rate of dropout due to treatment intolerance, a per-protocol analysis was conducted and indicates a possible benefit in treatment-adherent individuals [9] . Retrospective data also suggests that IPF patients receiving invasive ventilation and corticosteroids who also receive co-trimoxazole or a macrolide antibiotic have a better prognosis compared with not receiving these agents [30] . Interpretation of per-protocol and retrospective analyses Increased microaspiraƟon from GER?
FIGURE 2. Summary of hypotheses and evidence for the role of bacteria in idiopathic pulmonary fibrosis (IPF) pathogenesis. Shown is a graphical representation of evidence for a role of the lung microbiome in IPF pathogenesis. Given existing evidence, it is plausible that lung bacteria may represent the source of repetitive epithelial injury, activation of host innate immune system response, and drive progressive lung scar formation. These microbiome aberrations may arise from abnormal gain of bacterial burden via increased microaspiration due to GER, highly prevalent in IPF patients [6 & ,7,17,22] ; and/or slowed removal of bacteria from the lungs due to impaired mucocilliary clearance [7, 20, 21] . This may lead to increased bacterial burden and/or presence of potential pathogens in the lungs [5] [6] [7] . Host [8] . In the same report, immunization against the pneumococcal virulence factor, pneumolysin, prevents fibrosis exacerbation [8] .
Additional work is needed to determine the mechanism by which specific organisms result in propagation of fibrosis, and the role of immunization and antibiotics in limiting their impact on disease progression in humans with IPF. Another important treatment consideration is the role played by GER in shaping the lung microbiome in IPF. GER is prevalent, affecting up to 88% of IPF patients [31] . Recent data suggests that the lung microbiome is shaped in large part by silent microaspiration of bacteria from the oropharynx [12, 13, 14 & ]. Increased bacterial burden in the oropharynx as a result of GER, with subsequent immigration into the lungs via microaspiration, is one plausible explanation for the finding of increased bacterial burden in IPF lungs compared with controls [6 & ,7] . Limited-quality retrospective data suggest a benefit of medical [22] and surgical (i.e., laparoscopic fundoplication) [32] 
CONCLUSION
Advances in molecular sequencing technology in the last decade have allowed study of the role of the microbiome in health and disease. It has become clear that the lung contains a dynamic community of microbes in health, and patients with interstitial lung disease may have systematic derangements in bacterial community composition. Evidence suggests that knowledge of lung microbiome composition in IPF may serve as a prognostic biomarker, a therapeutic target, or provide an explanation for disease pathogenesis.
